Fastest customizable press release news feed in the world
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition. "On behalf of the Board of Directors and our NervGen employees, I want to thank Bill for
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the Company will present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium, which is being
VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced its Board of Directors has unanimously appointed Adam Rogers, MD, as President and Chief Executive Officer (CEO), effective immediately. Dr. Rogers will continue leading the Company's growth and execution of its mission to transform the lives of individuals living with spinal cord injury. The Board's decision reflects its confidence in Dr. Rogers' leadership,
VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company will ring the closing bell at the Nasdaq Stock Market (Nasdaq) on Thursday, January 22, 2026 in New York City. Adam Rogers, MD, Chairman and Interim Chief Executive Officer will be joined by members of the NervGen management team, Board of Directors, advisors, and other guests. "We are honored to participate in the Nasdaq closing bell ceremon
6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)
6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)
S-8 - NERVGEN PHARMA CORP. (0001751912) (Filer)
Live Leadership Updates
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition. "On behalf of the Board of Directors and our NervGen employees, I want to thank Bill for
VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced its Board of Directors has unanimously appointed Adam Rogers, MD, as President and Chief Executive Officer (CEO), effective immediately. Dr. Rogers will continue leading the Company's growth and execution of its mission to transform the lives of individuals living with spinal cord injury. The Board's decision reflects its confidence in Dr. Rogers' leadership,